Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.48.30 CHF
Change Today +0.60 / 1.26%
Volume 1.3K
As of 11:43 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

bachem holding ag-reg b (BANB) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/14 - SFr.50.90
52 Week Low
01/23/15 - SFr.41.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BACHEM HOLDING AG-REG B (BANB)

Related News

No related news articles were found.

bachem holding ag-reg b (BANB) Related Businessweek News

No Related Businessweek News Found

bachem holding ag-reg b (BANB) Details

Bachem Holding AG, a technology-based biochemicals company, provides various services to the pharmaceutical and biotechnology industries primarily in Europe and North America. The company is engaged in the process development; and the manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as biochemicals for research purposes. It offers research products, which include catalog products comprising amino acid derivatives, peptides, non-peptidic biochemicals, immunology products, and other biochemicals in various packaging sizes for peptide research, small scale peptide synthesis, or other research area; Melusine venom libraries, including common venom discovery collections, rare venom discovery collections, rare spider venom collections, and snake venom collections for discovering new drug candidates; sterile peptides under the Clinalfa brand; and custom synthesis service for peptides and amino acids. The company also provides API products, including generic APIs that are used in the fields of cancer, diabetes, obesity, fertility, and others; and new chemical entities. In addition, the company offers customer support services, such as formulation development; sterile tox-vials; compatibility studies; stress tests; post-release stability studies; chemistry, manufacturing, and control documentation for Investigational Medicinal Product Dossier and Investigational New Drug services; and other services. Bachem Holding AG was founded in 1971 and is headquartered in Bubendorf, Switzerland.

662 Employees
Last Reported Date: 08/29/14
Founded in 1971

bachem holding ag-reg b (BANB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.398.0K
Compensation as of Fiscal Year 2013.

bachem holding ag-reg b (BANB) Key Developments

Bachem Holding AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Bachem Holding AG Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Bachem Holding AG Announces Unaudited Consolidated Earnings Results for the First Half Year Ended June 30, 2014; Provides Profit Guidance for the Second Half of 2014

Bachem Holding AG announced unaudited consolidated earnings results for the first half year ended June 30, 2014. For the period, the company reported sales of CHF 86,723,000 against CHF 81,757,000 a year ago. Operating income (EBIT) was CHF 16,426,000 CHF 12,757,000 a year ago. Ordinary income before taxes was CHF 15,851,000 against CHF 13,031,000 a year ago. Net income was CHF 12,421,000 or CHF 0.92 per share basic and diluted against CHF 10,422,000 or CHF 0.77 per share basic and diluted a year ago. Cash flows from operating activities was CHF 19,322,000 against CHF 25,039,000 a year ago. Investments in property, plant and equipment was CHF 3,300,000 against CHF 3,163,000 a year ago. Investments in intangible assets were CHF 943,000 against CHF 1,416,000 a year ago. The company announced that renewed increase in profitability achieved in the first half is expected to be maintained in the second half, which underscores the company's potential for further profit growth.

Bachem Group Announces Change of Chief Technology Officer, Effective January 1, 2015

Bachem announced that Dr. Gunther Loidl will succeed Dr. Daniel Erne as Chief Technology Officer of Bachem Group on January 1, 2015. Dr. Daniel Erne officially retires on that date yet will continue to serve the company in an advisory capacity.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BANB:SW SFr.48.30 CHF +0.60

BANB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BANB.
View Industry Companies

Industry Analysis


Industry Average

Valuation BANB Industry Range
Price/Earnings 23.1x
Price/Sales 3.4x
Price/Book 1.8x
Price/Cash Flow 11.7x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BACHEM HOLDING AG-REG B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at